Chronic Kidney Disease

Gerald B. Appel, MD discusses the prevalence of IgAN in various populations and the heterogeneity of the disease.

A panel of glomerular disease specialists provide an overview of immunoglobulin A nephropathy (IgAN).

Kim Zuber, PA-C, and Jane Davis, DNP, provide perspective on guideline recommendations for the management of hepatitis C in people with chronic kidney disease from the Kidney Disease Improving Global Outcomes.

Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.

The 2022 updated guidelines includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease.

Results from the REGARDS study suggest traditional CKD risk factors were associated with higher risk of incident CKD and eGFR decline in Black individuals, compared to White individuals.

Using data from a trio of trials, investigators provide insight into the potential benefits of combination therapy with SGLT2 inhibitors and RAAS inhibition on event-free survival among patients with chronic kidney disease without diabetes.

Kim Zuber, MS, PA-C, and Jane Davis, DNP, provide perspective on the recent consensus statement on management of chronic kidney disease from the American Diabetes Association and the Kidney Disease Improving Global Outcomes group.

An analysis of data from the FIDELITY program suggests use of finerenone reduced negative heart failure outcomes in people with diabetes and chronic kidney disease, regardless of baseline kidney function.

Released on October 21, the special joint report from the Obesity Society and National Kidney Foundation outlines the hurdles, optimization strategies, and research needs for the management of coexisiting obesity and chronic kidney disease identified during a multispecialty, scientific workshop held in April 2021.

In an interview at the 6th annual Cardio-Endo-Renal Collaborative from Physicians' Education Resource, Amy Mottl, MD, provides perspective on recent data from the CURE-CKD registry and problems facing nephrologists as they cope with an increasing prevalence of diabetes.

Kim Zuber, PA-C, and Jane Davis, DNP, provide perspective on the new National Kidney Foundation and the American Society of Nephrology formula for calculating eGFR.

An analysis of data from more than 640,000 people with diabetes recorded between 2015-2020 is providing new insight into what study investigators are calling "troubling" trends in the incidence of CKD in the face a growing diabetes epidemic.

An analysis of data from more than 5500 people with type 1 diabetes and preserved kidney function at baseline suggests patients of African Caribbean ethnicity had a more than 50% greater risk of kidney function decline of 50% or greater than patients of other ethnic backgrounds.

An analysis of the FIDELITY program from ESC Congress 2022 details an 11% reduction in risk of all-cause mortality and a 25% reduction in risk of sudden cardiac death among patients with type 2 diabetes and chronic kidney disease.

After leading a session on the topic at ADCES, Sara Reece, PharmD, sat down to discuss the latest updates in chronic kidney disease management among patients with type 2 diabetes.

An analysis of patient data from the Chronic Renal Insufficiency Cohort Study suggests increased levels of serum aldosterone were associated with an increased risk of chronic kidney disease progression.

Data from a major trial detail the cardiorenal benefits of dapagliflozin use among patients with type 2 diabetes based on use of background cardiovascular medications.

An analysis of real-world EHR data from more than 900,000 statin users suggests use of rosuvastatin was associated with an 8% greater risk of hematuria, a 17% greater risk of proteinuria, and a 15% higher risk of developing kidney failure requiring replacement therapy such as dialysis or transplantation compared to atorvastatin use.

New research is underlining the importance of physical activity for extending longevity in adults with chronic kidney disease.

An analysis of patients with CKD from the CRIC study demonstrates those with the highest levels of physical activity had reductions in risk of 36%, 29%, and 53% for atherosclerotic events, incident heart failure, and cardiovascular mortality, respectively, compared to those with the lowest levels.

A recent analysis of the ISCHEMIA program suggests invasive management of chronic coronary disease appeared to provide a greater degree of benefit in those with less advanced stages of chronic kidney disease.

New data from a study performed by investigators at UVA Health details the accuracy of blood glucose measurements with factory-calibrated CGMs in patients undergoing dialysis.

New research from Indiana University details the impact of an invasive management strategy compared to medical management among patients with NSTEMI and chronic kidney disease across the spectrum of CKD severity.

An analysis of 20 randomized clinical trials comparing empagliflozin against placebo therapy in patients with type 2 diabetes suggests use of the SGLT2 inhibitor could reduce risk of developing kidney stones by nearly 40%.

After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.

Hiddo Heerspink, PharmD, PhD, discusses a SURPASS-4 analysis examining kidney outcomes among patients receiving tirzepatide vs insulin glargine and provides perspective on the next steps for research as well as education.

An analysis of SURPASS-4 data presented at ADA 2022 details the apparent reduction in progression of chronic kidney disease observed with use of tirzepatide compared to insulin glargine in the phase 3 trial, with a 41% reduction in progression of CKD in T2D.

Naomi Fisher, MD, offers perspective on the changing landscape of diabetes management and how the addition of new agents to the ADA's Standards of Care might impact care of patients.

An analysis of data from more than 75,000 patients with diabetic kidney disease details the risk of fracture among new users of SGLT2 inhibitors compared to new users of DPP-4 inhibitors.